The role of pharmacists in the management of autism spectrum disorder: A survey to determine the knowledge and perception of the parents

Year 2019, Volume: 49 Issue: 3, 180 - 185, 01.12.2019

Zeliha Pala Kara Büşra Çakır Deniz Kaleli Durman B. Sönmez Uydeş Doğan

Abstract

DOI: 10.26650/IstanbulJPharm.2019.19042

Background and aims: Autism spectrum disorder (ASD) is one of the neuropsychiatric disorders of childhood and has many causes including genetic, neurobiological, environmental as well as other risk factors that can trigger the disorder. The aim of this survey is to determine the knowledge of the families about ASD, the most prescribed medications, their side effects and the alternative therapies used besides to the pharmacological treatment.

Methods: This study was survey-based and conducted among parents of children with ASD (N=50).

Results : Risperidone, aripiprazole, and valproate were the most prescripted drugs (64%) and weight gain (n=14), increased aggressive behavior (n=11) and drowsiness/sedation (n=11) were reported as the main side effects. Besides to pharmacological therapy, most of ASD children have used complementary and alternative medicine like gluten and casein-free diet (n =23) or the sugar diet (n=15) as well as omega-3 (n=43), multivitamins (n=40), heavy metal chelation agents (n=27), vitamin B12 (n=18), zinc (n=17) vitamin D (n=9), and probiotics (n= 7).

Conclusion: It is revealed that pharmacists should be able to inform the parents about the general characteristics of ASD, to inform the parents about new treatment approaches and providing rational use of prescribed drugs in children with autism.

You may cite this article as: Pala Kara Z, Çakır B, Kaleli Durman D, Uydeş Doğan S (2019). The role of pharmacists in the management of autism spectrum disorder: A survey to determine the knowledge and perception of the parents. Istanbul J Pharm 10.26650/IstanbulJPharm.2019.19042.

Keywords

Autism spectrum disorder, pharmacist role, pharmacological therapy, complemenatry and alternative medicine

References

• Aman MG, Farmer CA, Hollway J, Arnold LE. (2008) Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 17(4): 713–738. Baumer N, Spence SJ. (2018) Evaluation and Management of the Child With Autism Spectrum Disorder. Continuum (Minneap Minn) 24(1, Child Neurology):248-275. Bolton P, Macdonald H, Pickles A, Rios P, Goode S, Crowson M, et al. (1994) A case-control family history study of autism. J Child Psychol Psychiatry 35(5): 877–900. Breik N, Kuo IF, Bugden S, Moffat M, Alessi-Severini S. (2018) Treating Children with ASD: The Perspective of Caregivers. J Pharm Pharm Sci 21(1):74-87. Cattane N, Richetto J, Cattaneo A. (2018) Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms. Neurosci Biobehav Rev 7634(17): 30972-7. Christensen D L, Baio J, Van Naarden BK, Bilder D, Charles J, Constantino J N, et al. (2016) Centers for Disease Control and Prevention Prevalence and characteristics of autismspectrumdisorder among children aged 8 years—Autismand Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveillance Summaries 65(3): 1–23. Davis TN, O-Reilly M, Kang S, et al. (2012) Chelation treatment for autism spectrum disorders: a systematic review. Res Autism Spectr Disord 7:49–55. DeFilippis M. (2018) The Use of Complementary Alternative Medicine in Children and Adolescents with Autism Spectrum Disorder. Psychopharmacol Bull 48(1):40-63. DiGuiseppi C, Hepburn S, Davis JM, Fidler DJ, Hartway S, Lee N.R, et al. (2010) Screening for autism spectrum disorders in children with down syndrome. J Dev Behav Pediatr 31:181–191. Emberti Gialloreti L, Mazzone L, Benvenuto A, Fasano A, Alcon AG, Kraneveld A, et al.(2019) Risk and Protective Environmental Factors Associated with Autism Spectrum Disorder: Evidence-Based Principles and Recommendations. J Clin Med 8(2): 217-240. Goel R, Hong JS, Findling RL, Ji NY. (2018) An update on pharmacotherapy of autism spectrum disorder in children and adolescents. Int Rev Psychiatry 30(1):78-95. Gyawali S and Patra BN.(2019) Autism spectrum disorder: Trends in research exploring etiopathogenesis. Psychiatry Clin Neurosci. Doi: 10.1111/pcn.12860. Hall SS, Lightbody AA, Reiss AL. (2008) Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am J Ment Retard 113(1): 44–53. Hellings JA, Nickel EJ, Weckbaugh M, McCarter K, Mosier M, Schroeder SR. (2205) The overt aggression scale for rating aggression in outpatient youth with autistic disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 17(1):29-35. Höfer J, Hoffmann F, Kamp-Becker I, Küpper C, Poustka L, Roepke S, et al. (2019) Complementary and alternative medicine use in adults with autism spectrum disorder in Germany: results from a multi-center survey. BMC Psychiatry 19(1):53. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 35(4):990-8. James S, Stevenson SW, Silove N, Williams K. (2015) Chelation for autism spectrum disorder (ASD). Kawicka A, Regulska-Ilow B.(2013) How nutritional status, diet and dietary supplements can affect autism. A review. Rocz Panstw Zakl Hig 64(1):1-12. Lovato DV, Herai RR, Pignatari GC, Beltrão-Braga PCB. (2019) The Relevance of Variants With Unknown Significance for Autism Spectrum Disorder Considering the Genotype-Phenotype Interrelationship. Front Psychiatry 10:409. Luleci NE, Hidiroglu S, Karavus M, Karavus A, Sanver FF, Ozgur F, Celik M, Celik SC.(2016) The pharmacists' awareness, knowledge and attitude about childhood autism in Istanbul. Int J Clin Pharm 38(6):1477-1482. National Institute of Mental Health (2018). Autism Spectrum Disorder. Retrieved from https://www.nimh.nih.gov/health/topics/autism-spectrum-disorders Novaes CM, Pondé MP, Freire AC. (2008) Control of psychomotor agitation and aggressive behavior in patients with autistic disorder: a retrospective chart review. Arq Neuropsiquiatr 66(3B): 646-51. Oshikoya KA, Carroll R, Aka I, Roden DM, Van Driest SL. (2019) Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study. Drugs Real World Outcomes 6(2):59-71. Pelch KE, Bolden AL, Kwiatkowski CF. (2019) Environmental Chemicals and Autism: A Scoping Review of the Human and Animal Research. Environ Health Perspect 127(4): 046001-12. Posey DJ, Stigler KA, Erickson CA, McDougle CJ. (2008) Antipsycohtics in the treatment of autism. J Clin Invest 118(1): 6–14. Shafiq S, Pringsheim T. (2018) Using antipsychotics for behavioral problems in children. Expert Opin Pharmacother 19(13):1475-1488. Sharma SR, Gonda X, Tarazi FI. (2018) Autism Spectrum Disorder: Classification, diagnosis and therapy. Pharmacol Ther 190:91-104. Tye C, Runicles AK, Whitehouse AJO, Alvares GA. (2019) Characterizing the Interplay Between Autism Spectrum Disorder and Comorbid Medical Conditions: An Integrative Review. Front Psychiatry 9:751. Wink LK, Pedapati EV, Horn PS, McDougle CJ, Erickson CA. (2017) Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. J Child Adolesc Psychopharmacol 27(1): 91–94. Wongpakaran R, Suansanae T, Tan-Khum T, Kraivichian C, Ongarjsakulman R, Suthisisang C. (2017) Impact of providing psychiatry specialty pharmacist intervention on reducing drug-related problems among children with autism spectrum disorder related to disruptive behavioural symptoms: A prospective randomized open-label study. J Clin Pharm Ther 42(3):329-336.